Last reviewed · How we verify
Droxidopa Oral Product
Noradrenergic neuron stimulation
Noradrenergic neuron stimulation Used for Neurogenic orthostatic hypotension.
At a glance
| Generic name | Droxidopa Oral Product |
|---|---|
| Also known as | NORTHERA, L-DOPS |
| Sponsor | Stephen G. Kaler |
| Drug class | Amino acid precursor |
| Target | Norepinephrine |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
Droxidopa is a synthetic amino acid that acts as a precursor to norepinephrine, increasing its levels in the central nervous system and stimulating noradrenergic neurons.
Approved indications
- Neurogenic orthostatic hypotension
Common side effects
- Nausea
- Headache
- Dizziness
Key clinical trials
- Phase I/II Study of NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes Disease. (PHASE1, PHASE2)
- Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure (PHASE1)
- Droxidopa / Pyridostigmine in Orthostatic Hypotension (PHASE2)
- Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury (PHASE2)
- Treatment of Orthostatic Hypotension (PHASE2, PHASE3)
- Effect of L-Dihydoxyphenylserine on Locomotion, Postural Stability, and Fall Risk Reduction in Parkinson Disease (PHASE2)
- Augmenting Effects of L-DOPS With Carbidopa and Entacapone (PHASE1, PHASE2)
- Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |